Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases

This is a clinical trial studying intravenous infusions of allogeneic gamma delta T cells after receiving low dose radiotherapy in participants with locally advanced or metastatic non-small cell lung cancer or solid tumors with bone metastases to evaluate the safety and efficacy of combining immunotherapy with radiation therapy.

Trial Details

NCT ID
NCT06069570
Phase
PHASE1
Sponsor
Kiromic BioPharma Inc.
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • KB-GDT-01
Locations (sample)
  • Tucson, Arizona, United States|32.22174,-110.92648
  • Beverly Hills, California, United States|34.07362,-118.40036
  • Pittsburgh, Pennsylvania, United States|40.44062,-79.99589
  • Tyler, Texas, United States|32.35126,-95.30106
  • Norfolk, Virginia, United States|36.84681,-76.28522

Key Eligibility Criteria

  • Signed and dated informed consent form.
  • Male or female, \> 18 years old.
  • Minimum body weight of 50 kilograms (kg).
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →